Civi Biopharma, Inc.
CiVi Biopharma is a clinical-stage biotechnology company focused on creating novel cardiovascular and metabolic therapies. The company develops assets in various stages of development, including intravenous iloprost for severe frostbite and oral PCSK9 inhibitors for cardiovascular disease. Founded in 2017 and headquartered in Chevy Chase, MD, CiVi Biopharma aims to deliver meaningful value to patients through innovative treatments.
Industries
Nr. of Employees
small (1-50)
Civi Biopharma, Inc.
5425 Wisconsin Avenue, 6th Floor, Chevy Chase, MD 20815
Patents
Products
CiVi 008
A third-generation antisense oligonucleotide designed to inhibit PCSK9 mRNA as an oral treatment to lower LDL-cholesterol and prevent atherosclerotic cardiovascular disease.
CiVi 030
An intravenous formulation of iloprost, developed as a vasoactive, platelet-inhibiting agent with anti-inflammatory and anti-fibrotic properties for treatment of severe frostbite and related vascular conditions.
CiVi 008
A third-generation antisense oligonucleotide designed to inhibit PCSK9 mRNA as an oral treatment to lower LDL-cholesterol and prevent atherosclerotic cardiovascular disease.
CiVi 030
An intravenous formulation of iloprost, developed as a vasoactive, platelet-inhibiting agent with anti-inflammatory and anti-fibrotic properties for treatment of severe frostbite and related vascular conditions.
Expertise Areas
- Antisense oligonucleotide therapeutics
- Oral drug formulation for oligonucleotides
- Preclinical pharmacology and toxicology (non-human primate)
- Clinical trial management (Phase I–III)
Key Technologies
- Antisense oligonucleotides
- RNA-targeted therapeutics
- Oral drug delivery formulation
- Intravenous formulation development